GT
ACOR

Glenmede Trust’s Acorda Therapeutics ACOR Stock Holding History

Glenmede Trust’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Hold
0
– – – 2623
2020
Q2 		– Sell
-10
Closed -$1.06K – 2671
2020
Q1 		$1K Hold
10
– – ﹤0.01% 2964
2019
Q4 		$1K Hold
10
– – ﹤0.01% 2964
2019
Q3 		$2 Sell
10
-1,186
-99% -$645K ﹤0.01% 2880
2019
Q2 		$1.1K Buy
1,196
+3
+0.3% +$3.69K ﹤0.01% 728
2019
Q1 		$1.9K Buy
1,193
+2
+0.2% +$3.6K 0.01% 639
2018
Q4 		$2.23K Hold
1,191
– – 0.01% 602
2018
Q3 		$2.81M Hold
1,191
– – 0.01% 580
2018
Q2 		$4.1M Buy
1,191
+5
+0.4% +$15.3K 0.02% 495
2018
Q1 		$3.05M Hold
1,186
– – 0.01% 580
2017
Q4 		$3.05M Sell
1,186
-1
-0.1% -$2.84K 0.01% 580
2017
Q3 		$3.37M Buy
1,187
+674
+131% +$1.78M 0.01% 552
2017
Q2 		$1.29M Hold
513
– – 0.01% 726
2017
Q1 		$1.29M Buy
513
+2
+0.4% +$5.76K 0.01% 726
2016
Q4 		$1.15M Sell
511
-95
-16% -$226K 0.01% 723
2016
Q3 		$1.52M Sell
606
-80
-12% -$239K 0.01% 680
2016
Q2 		$2.1M Buy
686
+278
+68% +$904K 0.01% 608
2016
Q1 		$1.29M Buy
408
+1
+0.2% +$4.15K 0.01% 687
2015
Q4 		$2.09M Sell
407
-103
-20% -$450K 0.01% 596
2015
Q3 		$1.62M Buy
510
+228
+81% +$884K 0.01% 636
2015
Q2 		$1.13M Hold
282
– – 0.01% 725
2015
Q1 		$1.12M Hold
282
– – 0.01% 742
2014
Q4 		$1.38M Hold
282
– – 0.01% 646
2014
Q3 		$1.14M Buy
+282
New +$1.06M 0.01% 653

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Glenmede Trust's ACOR Position: Q3 2020 in Review

Glenmede Trust held its Acorda Therapeutics (ACOR) position steady in Q3 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

Glenmede Trust first reported a position in ACOR in Q3 2014 and has held it in 23 quarters since. The position peaked at $4.1M in Q2 2018. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • Glenmede Trust held 0 shares of Acorda Therapeutics worth $0 as of Q3 2020.
  • Glenmede Trust left its Acorda Therapeutics share count unchanged in Q3 2020.
  • Acorda Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q3 2020, its #2623 holding.
  • Glenmede Trust first reported a position in Acorda Therapeutics in Q3 2014 and has held it in 23 quarters since.
  • Glenmede Trust's Acorda Therapeutics position peaked at $4.1M in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on Glenmede Trust's 13F filing for Q3 2020, filed 16 Nov 2020.